Laboratorios Farmaceuticos ROVI Stock | ROVI.MC | ES0157261019 | A0M0GQ

Date	Laboratorios Farmaceuticos ROVI Price
9/13/2024	73.70 undefined
9/12/2024	73.80 undefined
9/11/2024	75.10 undefined
9/10/2024	76.45 undefined
9/9/2024	82.25 undefined
9/6/2024	80.80 undefined
9/5/2024	78.95 undefined
9/4/2024	78.40 undefined
9/3/2024	78.55 undefined
9/2/2024	79.10 undefined
8/30/2024	79.55 undefined
8/29/2024	78.30 undefined
8/28/2024	77.80 undefined
8/27/2024	76.80 undefined
8/26/2024	76.95 undefined
8/23/2024	77.35 undefined
8/22/2024	76.90 undefined
8/21/2024	76.20 undefined
8/20/2024	76.75 undefined
8/19/2024	76.55 undefined

Date	Laboratorios Farmaceuticos ROVI Revenue	Laboratorios Farmaceuticos ROVI EBIT	Laboratorios Farmaceuticos ROVI Net Income
2028e	1.3 B undefined	463.34 M undefined	410.26 M undefined
2027e	1.25 B undefined	458.67 M undefined	352.89 M undefined
2026e	1.09 B undefined	370.86 M undefined	276.89 M undefined
2025e	908.19 M undefined	273.42 M undefined	205.61 M undefined
2024e	820.13 M undefined	223.52 M undefined	169.14 M undefined
2023	829.51 M undefined	220.25 M undefined	170.34 M undefined
2022	817.7 M undefined	255.85 M undefined	199.67 M undefined
2021	648.68 M undefined	183.07 M undefined	153.08 M undefined
2020	419.96 M undefined	78.77 M undefined	61.06 M undefined
2019	381.31 M undefined	43.18 M undefined	39.27 M undefined
2018	303.2 M undefined	17.46 M undefined	17.9 M undefined
2017	275.65 M undefined	19.01 M undefined	17.24 M undefined
2016	265.17 M undefined	28.3 M undefined	26.09 M undefined
2015	246.01 M undefined	21.84 M undefined	19.81 M undefined
2014	238.05 M undefined	27.43 M undefined	24.12 M undefined
2013	217.6 M undefined	25.4 M undefined	23 M undefined
2012	201.9 M undefined	21.7 M undefined	19.5 M undefined
2011	184.7 M undefined	19 M undefined	18.1 M undefined
2010	158.6 M undefined	26 M undefined	24.6 M undefined
2009	141.8 M undefined	25.5 M undefined	20.1 M undefined
2008	127.5 M undefined	28.3 M undefined	23.5 M undefined
2007	100.7 M undefined	18.4 M undefined	15 M undefined
2006	105 M undefined	13.4 M undefined	10.9 M undefined
2005	82.6 M undefined	3.3 M undefined	4.1 M undefined
2004	63.7 M undefined	3.5 M undefined	14.5 M undefined

	Revenue	EBIT	Net Income
2004	63.7 M EUR	3.5 M EUR	14.5 M EUR
2005	82.6 M EUR	3.3 M EUR	4.1 M EUR
2006	105 M EUR	13.4 M EUR	10.9 M EUR
2007	100.7 M EUR	18.4 M EUR	15 M EUR
2008	127.5 M EUR	28.3 M EUR	23.5 M EUR
2009	141.8 M EUR	25.5 M EUR	20.1 M EUR
2010	158.6 M EUR	26 M EUR	24.6 M EUR
2011	184.7 M EUR	19 M EUR	18.1 M EUR
2012	201.9 M EUR	21.7 M EUR	19.5 M EUR
2013	217.6 M EUR	25.4 M EUR	23 M EUR
2014	238.05 M EUR	27.43 M EUR	24.12 M EUR
2015	246.01 M EUR	21.84 M EUR	19.81 M EUR
2016	265.17 M EUR	28.3 M EUR	26.09 M EUR
2017	275.65 M EUR	19.01 M EUR	17.24 M EUR
2018	303.2 M EUR	17.46 M EUR	17.9 M EUR
2019	381.31 M EUR	43.18 M EUR	39.27 M EUR
2020	419.96 M EUR	78.77 M EUR	61.06 M EUR
2021	648.68 M EUR	183.07 M EUR	153.08 M EUR
2022	817.7 M EUR	255.85 M EUR	199.67 M EUR
2023	829.51 M EUR	220.25 M EUR	170.34 M EUR
2024e	820.13 M EUR	223.52 M EUR	169.14 M EUR
2025e	908.19 M EUR	273.42 M EUR	205.61 M EUR
2026e	1.09 B EUR	370.86 M EUR	276.89 M EUR
2027e	1.25 B EUR	458.67 M EUR	352.89 M EUR
2028e	1.3 B EUR	463.34 M EUR	410.26 M EUR

2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023

26.4	12.3	19.3	17.2	19.6	35.9	33.6	49.5	16.6	14.7	18.97	29.25	41.38	40.7	95.51	67.43	53.16	99.04	124.95	25.32
26.2	25.9	25.3	34.6	40.5	50.7	45.9	59.4	43.8	43.8	52.37	45.38	45.23	49.75	60.18	81.54	76.4	150.17	180.01	143.31
1.4	2.5	1.9	1.9	11.2	9.3	15.6	13	14.4	15.5	15.42	15.59	13.08	2.23	3.41	10.1	7.8	9.89	4.15	0
8.7	14	18.7	20.9	25.8	30.4	41.8	41.3	56.2	58.7	67.57	63.86	67.39	75.49	94.86	158.81	227.2	245.47	311.94	337.97
1.6	4.1	6.2	5.7	1.8	0	25	6	0	4.7	0	0	0	0	0.04	0	0.01	1.79	2.03	2.73
64.3	58.8	71.4	80.3	98.9	126.3	161.9	169.2	131	137.4	154.33	154.08	167.07	168.17	254	317.89	364.58	506.36	623.07	509.33
5.5	11.3	14	21.6	29.8	32.5	42.7	45.9	53.8	60.2	73.59	81.8	82.82	89.06	95.84	131.61	155.4	181.78	215.54	253.65
1.1	0.7	0	0	0	0	0	0	0	0	0	0	2.57	2.05	2.04	1.84	1.88	2.07	2.2	0.59
0	0	0	0.9	1.1	2.6	2.1	0.3	0.1	0.1	0.14	0.14	0.19	0.07	0.07	0.07	0.07	0.07	0.07	0.07
0	0	0	0.7	0.7	1	2.3	2.7	3.2	14.5	17.21	18.88	24.87	27.08	34.65	45.08	41.41	38.56	35.74	33.9
1.4	1.4	1.4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
8.6	17.2	16.5	8.6	5.2	2.4	3.9	10	34.2	23.6	8.35	8.94	10.32	11.96	16.11	14.73	11.11	3.85	2.08	2.34
16.6	30.6	31.9	31.8	36.8	38.5	51	58.9	91.3	98.4	99.29	109.76	120.78	130.22	148.7	193.33	209.86	226.31	255.63	290.55
80.9	89.4	103.3	112.1	135.7	164.8	212.9	228.1	222.3	235.8	253.62	263.85	287.85	298.38	402.7	511.21	574.44	732.68	878.7	799.88

10.7	9.9	3.5	3	3	3	3	3	3	3	3	3	3	3	3.36	3.36	3.36	3.36	3.24	3.24
0	0.9	0	0	0	0	0	0	0	0	0	0	0	0	87.64	87.64	87.64	87.64	87.64	87.64
30.2	34.4	37.9	48.9	72.2	85.4	103.1	112.9	125.5	142.2	158.28	169.9	189.11	197.09	205.28	241.73	302.89	446.1	456.7	556.19
0	0	0	0	-3.9	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
40.9	45.2	41.4	51.9	71.3	88.4	106.1	115.9	128.5	145.2	161.28	172.9	192.11	200.09	296.28	332.73	393.89	537.1	547.57	647.06
19	21.5	27.1	29.1	28.7	23.8	30.3	33.5	32	34.4	46.6	36.98	50.22	42.13	47.88	68.77	63.45	97.41	128.48	107.59
0	0	0	0	0	3	3.8	3.7	3.1	4.4	4.01	4.64	4.75	4.43	5.18	5.26	4.56	5.47	6.48	7.6
7.1	10.4	13.2	5.4	1.2	6.2	8.7	10.1	10.8	11.1	7.23	7.46	8.5	10.45	16.83	20.1	49.78	81.12	146.23	71.47
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	5.5	5.8	8.8	9.4	9.3	8.4	4.27	10.15	12.97	16.21	17.64	12.57	5.1	6.4	12.7	13.19
26.1	31.9	40.3	34.5	35.4	38.8	51.6	56.7	55.2	58.3	62.12	59.23	76.44	73.22	87.51	106.71	122.89	190.39	293.89	199.84
0	0.4	2.5	9.6	22.6	26	43.1	41.2	29.1	22.6	32.03	32.63	20.83	27.03	16.59	72.1	68.42	66.75	59.44	52.24
4	1.5	1.6	0.6	0.6	1.5	1.6	3.6	3.3	2.6	1.82	1.34	1.64	1.44	1.24	1.08	0.93	0.78	0.68	1.52
10	10.5	17.7	15.4	8.6	11.4	12.4	12.5	8.4	7.9	6.88	5.86	5.53	5.01	9.88	8.93	8.5	3.79	3.32	2.79
14	12.4	21.8	25.6	31.8	38.9	57.1	57.3	40.8	33.1	40.73	39.84	28	33.47	27.72	82.12	77.85	71.31	63.44	56.55
40.1	44.3	62.1	60.1	67.2	77.7	108.7	114	96	91.4	102.85	99.06	104.44	106.7	115.23	188.83	200.74	261.7	357.32	256.39
81	89.5	103.5	112	138.5	166.1	214.8	229.9	224.5	236.6	264.13	271.96	296.55	306.79	411.51	521.55	594.62	798.8	904.9	903.45

2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
17	3	14	19	28	24	25	18	20	24	25	20	27	17	16	41	72	182	257	220
1	1	1	0	1	2	3	4	5	6	8	9	11	11	12	18	19	21	22	24
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1	-6	-2	-13	-14	-11	6	-6	-6	-2	-13	0	9	-9	-20	-68	-47	-52	-43	-133
3	0	-3	-5	-2	-2	-14	-4	0	0	2	-1	-3	-1	0	0	1	-1	0	1
0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0	0	0
2	-1	2	0	7	2	2	1	2	2	3	1	3	0	3	8	6	23	43	40
22	0	10	1	12	13	21	12	19	29	23	29	45	18	8	-9	46	149	237	113
0	-4	-7	-11	-9	-5	-5	-8	-13	-24	-25	-19	-18	-19	-26	-40	-39	-40	-51	-55
-4	-13	-6	2	-8	0	-24	8	-39	-13	-8	-19	-16	-19	-26	-40	-39	-40	-57	-52
-4	-8	0	14	1	5	-18	16	-26	11	16	0	1	0	0	0	0	0	-5	3
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	7	9	4	4	8	3	-6	-8	2	5	-9	9	-9	25	-11	-4	-5	-12
0	0	0	0	-2	2	0	0	0	1	-1	-5	0	0	87	0	0	-36	-99	-81
0	0	3	0	-2	3	0	-5	-12	-13	-7	-7	-17	0	72	21	-21	-62	-154	-160
0	-1	-4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	2
0	0	0	-9	-3	-4	-7	-8	-6	-6	-8	-8	-6	-9	-5	-4	-9	-21	-51	-69
17	-14	6	4	2	16	-2	15	-32	2	7	2	12	0	54	-28	-14	45	25	-99
22.21	-5.21	3.14	-10.58	2.92	8.04	15.61	4.33	5.89	5.14	-2.05	9.49	27.45	-1.91	-17.93	-49.57	7.18	108.5	186.21	58.06
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Laboratorios Farmaceuticos ROVI Gross margin	Laboratorios Farmaceuticos ROVI Profit margin	Laboratorios Farmaceuticos ROVI EBIT margin	Laboratorios Farmaceuticos ROVI Profit margin
2028e	59.35 %	35.7 %	31.61 %
2027e	59.35 %	36.58 %	28.14 %
2026e	59.35 %	34.02 %	25.4 %
2025e	59.35 %	30.11 %	22.64 %
2024e	59.35 %	27.25 %	20.62 %
2023	59.35 %	26.55 %	20.53 %
2022	63.55 %	31.29 %	24.42 %
2021	59.32 %	28.22 %	23.6 %
2020	57.46 %	18.76 %	14.54 %
2019	56.31 %	11.33 %	10.3 %
2018	57.58 %	5.76 %	5.9 %
2017	60.77 %	6.9 %	6.25 %
2016	57.75 %	10.67 %	9.84 %
2015	60.54 %	8.88 %	8.05 %
2014	60.27 %	11.52 %	10.13 %
2013	60.98 %	11.67 %	10.57 %
2012	62.61 %	10.75 %	9.66 %
2011	62.43 %	10.29 %	9.8 %
2010	60.4 %	16.39 %	15.51 %
2009	67.28 %	17.98 %	14.17 %
2008	72.31 %	22.2 %	18.43 %
2007	68.22 %	18.27 %	14.9 %
2006	71.81 %	12.76 %	10.38 %
2005	71.91 %	4 %	4.96 %
2004	68.6 %	5.49 %	22.76 %

	Gross margin	EBIT margin	Profit margin
2004	68.6 %	5.49 %	22.76 %
2005	71.91 %	4 %	4.96 %
2006	71.81 %	12.76 %	10.38 %
2007	68.22 %	18.27 %	14.9 %
2008	72.31 %	22.2 %	18.43 %
2009	67.28 %	17.98 %	14.17 %
2010	60.4 %	16.39 %	15.51 %
2011	62.43 %	10.29 %	9.8 %
2012	62.61 %	10.75 %	9.66 %
2013	60.98 %	11.67 %	10.57 %
2014	60.27 %	11.52 %	10.13 %
2015	60.54 %	8.88 %	8.05 %
2016	57.75 %	10.67 %	9.84 %
2017	60.77 %	6.9 %	6.25 %
2018	57.58 %	5.76 %	5.9 %
2019	56.31 %	11.33 %	10.3 %
2020	57.46 %	18.76 %	14.54 %
2021	59.32 %	28.22 %	23.6 %
2022	63.55 %	31.29 %	24.42 %
2023	59.35 %	26.55 %	20.53 %
2024e	59.35 %	27.25 %	20.62 %
2025e	59.35 %	30.11 %	22.64 %
2026e	59.35 %	34.02 %	25.4 %
2027e	59.35 %	36.58 %	28.14 %
2028e	59.35 %	35.7 %	31.61 %

Date	Laboratorios Farmaceuticos ROVI Sales per Share	Laboratorios Farmaceuticos ROVI EBIT per share	Laboratorios Farmaceuticos ROVI Earnings per Share
2028e	25.05 undefined	0 undefined	7.92 undefined
2027e	24.2 undefined	0 undefined	6.81 undefined
2026e	21.03 undefined	0 undefined	5.34 undefined
2025e	17.53 undefined	0 undefined	3.97 undefined
2024e	15.83 undefined	0 undefined	3.26 undefined
2023	15.59 undefined	4.14 undefined	3.2 undefined
2022	15.29 undefined	4.79 undefined	3.73 undefined
2021	11.71 undefined	3.3 undefined	2.76 undefined
2020	7.58 undefined	1.42 undefined	1.1 undefined
2019	6.91 undefined	0.78 undefined	0.71 undefined
2018	5.92 undefined	0.34 undefined	0.35 undefined
2017	5.6 undefined	0.39 undefined	0.35 undefined
2016	5.41 undefined	0.58 undefined	0.53 undefined
2015	4.97 undefined	0.44 undefined	0.4 undefined
2014	4.77 undefined	0.55 undefined	0.48 undefined
2013	4.37 undefined	0.51 undefined	0.46 undefined
2012	4.06 undefined	0.44 undefined	0.39 undefined
2011	3.72 undefined	0.38 undefined	0.36 undefined
2010	3.19 undefined	0.52 undefined	0.49 undefined
2009	2.86 undefined	0.51 undefined	0.41 undefined
2008	2.56 undefined	0.57 undefined	0.47 undefined
2007	2.01 undefined	0.37 undefined	0.3 undefined
2006	2.1 undefined	0.27 undefined	0.22 undefined
2005	1.65 undefined	0.07 undefined	0.08 undefined
2004	1.27 undefined	0.07 undefined	0.29 undefined

	Sales per Share	EBIT per share	Earnings per Share
2004	1.27 EUR	0.07 EUR	0.29 EUR
2005	1.65 EUR	0.07 EUR	0.08 EUR
2006	2.1 EUR	0.27 EUR	0.22 EUR
2007	2.01 EUR	0.37 EUR	0.3 EUR
2008	2.56 EUR	0.57 EUR	0.47 EUR
2009	2.86 EUR	0.51 EUR	0.41 EUR
2010	3.19 EUR	0.52 EUR	0.49 EUR
2011	3.72 EUR	0.38 EUR	0.36 EUR
2012	4.06 EUR	0.44 EUR	0.39 EUR
2013	4.37 EUR	0.51 EUR	0.46 EUR
2014	4.77 EUR	0.55 EUR	0.48 EUR
2015	4.97 EUR	0.44 EUR	0.4 EUR
2016	5.41 EUR	0.58 EUR	0.53 EUR
2017	5.6 EUR	0.39 EUR	0.35 EUR
2018	5.92 EUR	0.34 EUR	0.35 EUR
2019	6.91 EUR	0.78 EUR	0.71 EUR
2020	7.58 EUR	1.42 EUR	1.1 EUR
2021	11.71 EUR	3.3 EUR	2.76 EUR
2022	15.29 EUR	4.79 EUR	3.73 EUR
2023	15.59 EUR	4.14 EUR	3.2 EUR
2024e	15.83 EUR	0 EUR	3.26 EUR
2025e	17.53 EUR	0 EUR	3.97 EUR
2026e	21.03 EUR	0 EUR	5.34 EUR
2027e	24.2 EUR	0 EUR	6.81 EUR
2028e	25.05 EUR	0 EUR	7.92 EUR

	Number of stocks
2004	50 M Aktien
2005	50 M Aktien
2006	50 M Aktien
2007	50 M Aktien
2008	49.9 M Aktien
2009	49.6 M Aktien
2010	49.7 M Aktien
2011	49.7 M Aktien
2012	49.7 M Aktien
2013	49.8 M Aktien
2014	49.89 M Aktien
2015	49.54 M Aktien
2016	49.03 M Aktien
2017	49.26 M Aktien
2018	51.22 M Aktien
2019	55.18 M Aktien
2020	55.39 M Aktien
2021	55.4 M Aktien
2022	53.47 M Aktien
2023	53.19 M Aktien
2024e	53.19 M Aktien
2025e	53.19 M Aktien
2026e	53.19 M Aktien
2027e	53.19 M Aktien
2028e	53.19 M Aktien

Date	Laboratorios Farmaceuticos ROVI Dividend
2028e	1.69 undefined
2027e	1.69 undefined
2026e	1.69 undefined
2025e	1.69 undefined
2024e	1.69 undefined
2023	1.29 undefined
2022	0.96 undefined
2021	0.38 undefined
2020	0.18 undefined
2019	0.08 undefined
2018	0.12 undefined
2017	0.18 undefined
2016	0.14 undefined
2015	0.17 undefined
2014	0.16 undefined
2013	0.14 undefined
2012	0.13 undefined
2011	0.17 undefined
2010	0.14 undefined
2009	0.09 undefined
2008	0.08 undefined

	Dividend	Dividend (Estimate)
2004	0 EUR	0 EUR
2005	0 EUR	0 EUR
2006	0 EUR	0 EUR
2007	0 EUR	0 EUR
2008	0.08 EUR	0 EUR
2009	0.09 EUR	0 EUR
2010	0.14 EUR	0 EUR
2011	0.17 EUR	0 EUR
2012	0.13 EUR	0 EUR
2013	0.14 EUR	0 EUR
2014	0.16 EUR	0 EUR
2015	0.17 EUR	0 EUR
2016	0.14 EUR	0 EUR
2017	0.18 EUR	0 EUR
2018	0.12 EUR	0 EUR
2019	0.08 EUR	0 EUR
2020	0.18 EUR	0 EUR
2021	0.38 EUR	0 EUR
2022	0.96 EUR	0 EUR
2023	1.29 EUR	0 EUR
2024e	0 EUR	1.69 EUR
2025e	0 EUR	1.69 EUR
2026e	0 EUR	1.69 EUR
2027e	0 EUR	1.69 EUR
2028e	0 EUR	1.69 EUR

Date	Laboratorios Farmaceuticos ROVI Payout ratio
2028e	20.23 %
2027e	19.99 %
2026e	19.6 %
2025e	21.09 %
2024e	19.27 %
2023	18.42 %
2022	25.59 %
2021	13.8 %
2020	15.88 %
2019	11.21 %
2018	34.55 %
2017	52.29 %
2016	26.12 %
2015	42.26 %
2014	33.35 %
2013	29.7 %
2012	32.54 %
2011	47.8 %
2010	28.78 %
2009	21.1 %
2008	16.66 %
2007	18.42 %
2006	18.42 %
2005	18.42 %
2004	18.42 %

	Payout ratio
2004	18.42 %
2005	18.42 %
2006	18.42 %
2007	18.42 %
2008	16.66 %
2009	21.1 %
2010	28.78 %
2011	47.8 %
2012	32.54 %
2013	29.7 %
2014	33.35 %
2015	42.26 %
2016	26.12 %
2017	52.29 %
2018	34.55 %
2019	11.21 %
2020	15.88 %
2021	13.8 %
2022	25.59 %
2023	18.42 %
2024e	19.27 %
2025e	21.09 %
2026e	19.6 %
2027e	19.99 %
2028e	20.23 %

Date	EPS Estimate	EPS Actual	Quarterly report
9/30/2020	0.18	0.31 (69.39 %)	2020 Q3
6/30/2020	0.14	0.28 (96.08 %)	2020 Q2
3/31/2020	0.14	0.25 (75.07 %)	2020 Q1
12/31/2019	0.08	0.16 (96.08 %)	2019 Q4
9/30/2019	0.13	0.26 (96.08 %)	2019 Q3
6/30/2019	0.09	0.17 (83.01 %)	2019 Q2
3/31/2019	0.09	0.12 (38.41 %)	2019 Q1
12/31/2018	0.01	0.04 (684.31 %)	2018 Q4
9/30/2018	0.06	0.16 (161.44 %)	2018 Q3
6/30/2018	0.13	0.01 (-92.46 %)	2018 Q2
12/31/2017	-0.06	-0.04 (34.64 %)	2017 Q4
12/31/2016	0.02	0.09 (336.27 %)	2016 Q4
3/31/2015	0.11	0.13 (12.96 %)	2015 Q1
9/30/2014	0.12	0.1 (-17.02 %)	2014 Q3
6/30/2014	0.14	0.18 (31.68 %)	2014 Q2
3/31/2014	0.17	0.12 (-29.54 %)	2014 Q1
12/31/2013	0.2	0.09 (-56.37 %)	2013 Q4
9/30/2013	0.15	0.1 (-34.62 %)	2013 Q3
6/30/2013	0.36	0.28 (-22.01 %)	2013 Q2
12/31/2012	0.08	0.06 (-26.47 %)	2012 Q4
9/30/2012	0.11	0.07 (-34.02 %)	2012 Q3
6/30/2012	0.1	0.16 (51.96 %)	2012 Q2
12/31/2011	0.01	0.05 (670.49 %)	2011 Q4
9/30/2011	0.09	0.06 (-38.88 %)	2011 Q3
6/30/2011	0.06	0.16 (171.36 %)	2011 Q2
12/31/2010	-0	0 (100 %)	2010 Q4
3/31/2010	0.1	0.1 (4.28 %)	2010 Q1
12/31/2009	0.09	0.06 (-32.4 %)	2009 Q4
9/30/2009	0.14	0.2 (43.16 %)	2009 Q3
6/30/2009	0.11	0.04 (-62.3 %)	2009 Q2
12/31/2008	0.12	0.07 (-38.81 %)	2008 Q4
9/30/2008	0.17	0.17 (5.33 %)	2008 Q3
6/30/2008	0.12	0.11 (-6.33 %)	2008 Q2
3/31/2008	0.14	0.12 (-14.52 %)	2008 Q1

%	Name	Stocks	Change	Date
57.52935 %	Norbel Invesrsiones, S.L.	29,811,821	0	3/5/2024
5.27443 %	Indumenta Pueri, S.L.	2,733,218	0	3/5/2024
1.69225 %	Capital Research Global Investors	876,925	876,925	3/31/2024
1.41879 %	T. Rowe Price International Ltd	735,222	2,678	3/31/2024
1.19703 %	The Vanguard Group, Inc.	620,301	3,998	3/31/2024
1.06231 %	Norges Bank Investment Management (NBIM)	550,492	-278,072	12/31/2023
0.82665 %	INVESCO Asset Management Limited	428,371	-106,389	1/23/2024
0.69000 %	RBC Global Asset Management (UK) Limited	357,561	-236	2/29/2024
0.65440 %	Dimensional Fund Advisors, L.P.	339,110	0	3/31/2024
0.61558 %	ProfitlichSchmidlin AG	318,996	-6,500	1/31/2024
0.57555 %	Wellington Management Company, LLP	298,249	-9,766	2/29/2024
0.55929 %	BNP Paribas Asset Management UK Limited	289,824	11,656	2/29/2024
0.51165 %	Victory Capital Management Inc.	265,137	29,576	12/31/2023
0.48608 %	BNP Paribas Asset Management Belgium S.A.	251,888	0	2/29/2024
0.43652 %	BlackRock Institutional Trust Company, N.A.	226,206	-1,015	3/31/2024
0.38151 %	Bestinver Gestión S.A., S.G.I.I.C.	197,699	-31,028	12/31/2023
0.35179 %	EDM Gestión S.A., S.G.I.I.C.	182,298	-54,499	12/31/2023
0.31582 %	Santander Asset Management	163,661	-545,418	12/31/2023
0.30876 %	Degroof Petercam Asset Management	160,000	0	12/31/2023
0.30417 %	Polar Capital LLP	157,620	-46,411	2/29/2024
0.26892 %	Capital World Investors	139,357	139,357	3/31/2024
0.22692 %	Amundi Asset Management, SAS	117,588	-1,667	3/31/2024
0.21648 %	Florida State Board of Administration	112,178	58,962	9/30/2022
0.21644 %	BNP Paribas Asset Management France SAS	112,158	44,866	3/31/2024
0.20320 %	Sycomore Asset Management	105,297	0	1/31/2024
0.18815 %	Mandatum Asset Management Ltd	97,500	97,500	6/30/2023
0.18401 %	DNCA Investments	95,355	-6,138	2/29/2024
0.17319 %	Valentum Asset Management SGIIC, S.A.	89,749	-20,000	12/31/2023
0.16255 %	RBC Global Asset Management Inc.	84,234	0	12/31/2023
0.15438 %	Fourton Rahastoyhtiö Oy	80,000	-10,000	9/30/2023
0.15299 %	BBVA Asset Management, S.A., S.G.I.I.C.	79,282	63,859	12/31/2023
0.14750 %	Santalucia AM, S.G.I.I.C	76,433	76,433	12/31/2023
0.14608 %	Société de Gestion Prévoir	75,700	6,500	11/30/2023
0.14227 %	Tocqueville Finance S.A.	73,722	46,475	12/31/2023
0.12851 %	Renta 4 Gestora, S.G.I.I.C., S.A.	66,592	976	12/31/2023
0.11935 %	Fidelity International	61,847	157	2/29/2024
0.11835 %	Mirabaud Asset Management Limited	61,327	7,043	12/31/2023
0.11578 %	Credit Mutuel Asset Management	60,000	0	2/29/2024
0.10517 %	Fondita Rahastoyhtiö Oy	54,500	0	2/29/2024
0.10356 %	Bellevue Asset Management AG	53,666	-9,743	2/29/2024
0.09649 %	Ruffer LLP	50,000	-32,000	6/30/2023
0.09431 %	JPMorgan Asset Management U.K. Limited	48,872	28,017	3/31/2024
0.09418 %	Fideuram Asset Management (Ireland) dac	48,802	-2,040	2/29/2024
0.09226 %	HSBC Global Asset Management (France) S.A.	47,807	0	12/31/2023
0.09222 %	Mellon Investments Corporation	47,788	2,607	3/31/2024
0.09107 %	BlackRock Advisors (UK) Limited	47,195	189	3/31/2024
0.08808 %	Goldman Sachs Asset Management International	45,644	-5,712	12/31/2023
0.08099 %	RAM Active Investments S.A.	41,970	13,772	12/31/2023
0.07879 %	Charles Schwab Investment Management, Inc.	40,829	-966	3/31/2024
0.07683 %	State Street Global Advisors (US)	39,812	0	3/31/2024
0.07640 %	Invesco Advisers, Inc.	39,589	-15,148	1/31/2024
0.07329 %	California State Teachers Retirement System	37,980	2,411	6/30/2023
0.07196 %	Schroder Investment Management North America Inc.	37,291	22,109	9/30/2022
0.07148 %	Quoniam Asset Management GmbH	37,040	37,040	12/31/2023
0.07073 %	Mapfre Inversión Dos, S.G.I.I.C., S.A.	36,650	-5,250	12/31/2023
0.06928 %	Andbank Wealth Management, SGIIC, S.A.U.	35,900	0	12/31/2023
0.05917 %	AllianceBernstein L.P.	30,660	-7,500	2/29/2024
0.05898 %	Montanaro Asset Management Limited	30,561	-4,298	2/29/2024
0.05340 %	Pictet Asset Management Ltd.	27,674	0	2/29/2024
0.05286 %	Mediolanum International Funds Limited	27,394	27,394	12/31/2023
0.05062 %	DWS Investment GmbH	26,229	56	3/31/2024
0.05033 %	Varianza Gestión SGIIC, SA	26,080	8,498	12/31/2023
0.04902 %	Singular Asset Management SGIIC SA.	25,400	25,400	12/31/2023
0.04841 %	Allianz Global Investors GmbH	25,085	9,417	2/29/2024
0.04828 %	Mapfre Asset Management, SGIIC, S.A.	25,019	2,819	6/30/2023
0.04824 %	Banque Degroof Petercam N.V.	25,000	0	12/31/2023
0.04640 %	SEI Investments Management Corporation	24,045	-3,845	3/31/2024
0.04628 %	SEB Investment Management AB	23,981	10,300	2/29/2024
0.04482 %	Trea Asset Management S.G.I.I.C., S.A.	23,227	3,533	12/31/2023
0.04349 %	BPI Gestão de Activos - S.G.F.I.M., S.A.	22,537	-4,000	2/29/2024
0.04299 %	Caixabank Asset Management SGIIC, S.A.U.	22,279	-13,724	12/31/2023
0.04224 %	Margetts Fund Management Limited	21,889	-2,874	12/31/2023
0.04199 %	J. Chahine Capital	21,757	1,013	2/29/2024
0.03956 %	Ibercaja Gestión S.G.I.I.C., S.A.	20,500	-73,500	12/31/2023
0.03750 %	Thrivent Asset Management, LLC	19,432	0	1/31/2024
0.03705 %	Portzamparc Gestion S.A.	19,200	0	3/31/2024
0.03694 %	Baillie Gifford & Co.	19,141	9,294	1/31/2024
0.03688 %	Kutxabank Gestion, SGIIC, S.A.U.	19,112	-8,713	2/29/2024
0.03584 %	Dimensional Fund Advisors, Ltd.	18,570	0	1/31/2024
0.03489 %	Federal Finance Gestion	18,079	-1,745	2/29/2024
0.03438 %	T. Rowe Price Investment Management, Inc.	17,817	2,224	2/29/2024
0.03363 %	Muza Gestión De Activos, S.G.I.I.C., S.A.	17,426	1,500	2/29/2024
0.03173 %	Grupo Catalana Occidente, S.A.	16,440	-16,510	12/31/2023
0.03103 %	Nuveen LLC	16,078	0	3/31/2024
0.02959 %	Eika Kapitalforvaltning AS	15,334	0	1/31/2024
0.02895 %	Urquijo Gestión, S.A., S.G.I.I.C., Sociedad Unipersonal	15,000	-20,000	12/31/2023
0.02895 %	Meeschaert Amilton Asset Management_NLE	15,000	15,000	9/30/2023
0.02871 %	Geode Capital Management, L.L.C.	14,875	0	2/29/2024
0.02756 %	UBS Asset Management (Switzerland)	14,284	367	3/31/2024
0.02702 %	Banque Nationale de Belgique S.A.	14,000	0	2/29/2024
0.02470 %	SPSW Capital GmbH	12,800	-4,700	1/31/2024
0.02466 %	AMUNDI IBERIA SGIIC SA	12,779	-1,138	12/31/2023
0.02200 %	Avantage Capital EAFI, SL	11,400	0	12/31/2023
0.02179 %	March Asset Management, S.G.I.I.C., S.A.U.	11,292	3,952	6/30/2023
0.02130 %	Credit Suisse Asset Management (Schweiz) AG	11,037	-69	2/29/2024
0.02103 %	Unigest, S.G.I.I.C., S.A.	10,900	0	12/31/2023
0.01990 %	Bankinter Gestión de Activos, SGIIC S.A.	10,310	-22,690	12/31/2023
0.01981 %	Operadora Valmex de Sociedades de Inversión S.A. de C.V.	10,267	-307	2/29/2024
0.01930 %	EB - Sustainable Investment Management GmbH	10,000	0	1/31/2024
0.01930 %	Artemis Investment Management LLP	10,000	0	12/31/2023

Name	Relationship	Two-week correlation	One-month correlation	Three-Month Correlation	Six-Month Correlation	One Year Correlation	Two-Year Correlation
Merck & Co	SupplierCustomer	0,42	-0,60	-0,77	-0,60	-	0,25
Enervit SpA	SupplierCustomer	0,17	-0,01	-0,01	0,13	0,07	0,80
Moderna	SupplierCustomer	0,15	0,28	0,56	0,36	-0,48	0,60
Novartis	SupplierCustomer	0,15	0,64	-0,81	-0,68	-0,34	-
Elecnor	SupplierCustomer	-0,01	-0,67	-0,75	-0,44	0,19	0,62
Astellas Pharma	SupplierCustomer	-0,02	0,53	-0,44	-0,34	-0,03	0,68

What values and corporate philosophy does Laboratorios Farmaceuticos ROVI represent?

Laboratorios Farmaceuticos ROVI SA represents values of innovation, integrity, and excellence in the pharmaceutical industry. With a strong corporate philosophy centered on the development and manufacturing of innovative medicines and healthcare products, ROVI prioritizes patient well-being and strives for scientific advancement. The company's commitment to research and development, along with its focus on partnerships with healthcare professionals and organizations, enables ROVI to provide innovative solutions that improve patients' lives. By embracing a culture of responsibility, transparency, and ethical practices, Laboratorios Farmaceuticos ROVI SA aims to contribute to global healthcare and deliver value to its stakeholders.

In which countries and regions is Laboratorios Farmaceuticos ROVI primarily present?

Laboratorios Farmaceuticos ROVI SA is primarily present in Spain, where the company is based. Additionally, ROVI has a global presence, with its products and services being available in several other countries and regions around the world. These include various European countries such as Germany, France, Italy, Portugal, and the United Kingdom. Furthermore, ROVI has a significant presence in the Americas, including Mexico, Brazil, and Colombia. With its international reach, Laboratorios Farmaceuticos ROVI SA has established a strong presence in both European and American markets, catering to a wide range of customers and expanding its global footprint.

What significant milestones has the company Laboratorios Farmaceuticos ROVI achieved?

Laboratorios Farmaceuticos ROVI SA has achieved several significant milestones throughout its history. One noteworthy achievement is its development of innovative pharmaceutical products, including advanced drug delivery systems and therapeutic solutions. The company has also gained recognition for its expertise in biopharmaceutical manufacturing and has successfully established numerous strategic partnerships globally. Additionally, Laboratorios Farmaceuticos ROVI SA has demonstrated consistent growth and profitability, expanding its market presence and enhancing shareholder value. These achievements reflect the company's commitment to delivering high-quality healthcare solutions and driving advancements within the pharmaceutical industry.

What is the history and background of the company Laboratorios Farmaceuticos ROVI?

Laboratorios Farmaceuticos ROVI SA is a renowned pharmaceutical company with an impressive history and background. Established in 1946, ROVI SA has consistently focused on developing and manufacturing innovative healthcare solutions. With its headquarters in Madrid, Spain, the company operates in various therapeutic areas, including Special Focused Medicines, Biosimilars, and Active Pharmaceutical Ingredients (APIs). ROVI SA has a strong commitment to research and development, striving to improve patients' quality of life through cutting-edge treatments. Over the years, the company has gained recognition and trust from healthcare practitioners and patients alike, solidifying its position as a prominent player in the pharmaceutical industry.

Who are the main competitors of Laboratorios Farmaceuticos ROVI in the market?

The main competitors of Laboratorios Farmaceuticos ROVI SA in the market include pharmaceutical companies such as Novartis, Pfizer, Johnson & Johnson, and Sanofi.

In which industries is Laboratorios Farmaceuticos ROVI primarily active?

Laboratorios Farmaceuticos ROVI SA is primarily active in the pharmaceutical industry.

What is the business model of Laboratorios Farmaceuticos ROVI?

The business model of Laboratorios Farmaceuticos ROVI SA focuses on pharmaceutical research, development, manufacturing, and commercialization. The company operates in the specialty pharmaceuticals industry and specializes in the production of injectable pharmaceuticals and various other drugs. Laboratorios Farmaceuticos ROVI SA collaborates with international partners for the licensing and distribution of its products. With a strong emphasis on innovation and quality, the company aims to provide healthcare solutions through its unique product portfolio. Laboratorios Farmaceuticos ROVI SA actively pursues partnerships and collaborations to expand its market reach and continuously improve its product pipeline.

What is the P/E ratio of Laboratorios Farmaceuticos ROVI 2024?

The Laboratorios Farmaceuticos ROVI P/E ratio is 23.18.

What is the P/S ratio of Laboratorios Farmaceuticos ROVI 2024?

The Laboratorios Farmaceuticos ROVI P/S ratio is 4.78.

What is the AlleAktien quality score of Laboratorios Farmaceuticos ROVI?

The AlleAktien quality score for Laboratorios Farmaceuticos ROVI is 9/10.

What is the revenue of Laboratorios Farmaceuticos ROVI 2024?

The expected Laboratorios Farmaceuticos ROVI revenue is 820.13 M EUR.

How high is the profit of Laboratorios Farmaceuticos ROVI 2024?

The expected Laboratorios Farmaceuticos ROVI profit is 169.14 M EUR.

What is the business model of Laboratorios Farmaceuticos ROVI

Laboratorios Farmaceuticos ROVI SA is a leading pharmaceutical company specializing in the development and production of biotechnological drugs, vaccines, and generics. The company was founded in Spain in 1946 and has since built an impressive track record. Today, ROVI is a global player with customers in over 80 countries worldwide. ROVI operates in three business segments: Innovation, Generics, and Specialties. In the Innovation segment, the company focuses on biotechnological drugs and vaccines, with a particular emphasis on tissue repair, kidney and liver diseases, and immuno-oncology. The pipeline of Innovation includes a variety of innovative drugs in various stages of clinical development. A significant milestone for the company was the successful approval of Doria®, an inactivated SARS-CoV-2 vaccine for individuals aged 18 years and older. In the Generics segment, ROVI focuses on high-quality generics for various diseases. The company has strong partnerships worldwide, giving it access to a broad network of producers and suppliers. ROVI is an important supplier to the public health sector in many countries. The Specialties segment comprises different products, such as contrast agents for medical imaging, wound care, and non-surgical wrinkle treatment. ROVI's product range includes a variety of drugs and vaccines for different diseases and applications. Some of the most well-known products are Envarsus® for preventing transplant rejection in kidney or liver transplantations, Bemiparin as an anticoagulant for the prevention and treatment of thrombosis, and Hepacare® for the treatment of Hepatitis C, used in countries like Pakistan to reduce the spread of the disease. To meet the growing needs of the healthcare market, ROVI has invested in research and development. The company has expanded its research and development pipeline and works on developing innovative drugs and products. ROVI is also known for investing in partnerships. The company collaborates closely with other bio-pharmaceutical companies and research institutes to develop new drugs. These partnerships also open up new markets and provide access to new technologies. In summary, ROVI SA has been active as a strategic and influential company in the biopharmaceutical world. Investments in research and development, innovation, and partnerships have contributed to ROVI's recognition in the industry. With a wide network of producers and suppliers worldwide and customers in over 80 countries, ROVI is globally present and has established a strong position in the public health sector.

What is the Laboratorios Farmaceuticos ROVI dividend?

Laboratorios Farmaceuticos ROVI pays a dividend of 0.96 EUR distributed over 1 payouts per year.

How often does Laboratorios Farmaceuticos ROVI pay dividends?

Laboratorios Farmaceuticos ROVI pays out a dividend 1 times a year.

What is the Laboratorios Farmaceuticos ROVI ISIN?

The ISIN of Laboratorios Farmaceuticos ROVI is ES0157261019.

What is the Laboratorios Farmaceuticos ROVI WKN?

The WKN of Laboratorios Farmaceuticos ROVI is A0M0GQ.

What is the Laboratorios Farmaceuticos ROVI ticker?

The ticker of Laboratorios Farmaceuticos ROVI is ROVI.MC.

How much dividend does Laboratorios Farmaceuticos ROVI pay?

Over the past 12 months, Laboratorios Farmaceuticos ROVI paid a dividend of 1.29 EUR . This corresponds to a dividend yield of about 1.76 %. For the coming 12 months, Laboratorios Farmaceuticos ROVI is expected to pay a dividend of 1.69 EUR.

What is the dividend yield of Laboratorios Farmaceuticos ROVI?

The current dividend yield of Laboratorios Farmaceuticos ROVI is 1.76 %.

When does Laboratorios Farmaceuticos ROVI pay dividends?

Laboratorios Farmaceuticos ROVI pays a quarterly dividend. This is distributed in the months of August, August, August, August.

How secure is the dividend of Laboratorios Farmaceuticos ROVI?

Laboratorios Farmaceuticos ROVI paid dividends every year for the past 21 years.

What is the dividend of Laboratorios Farmaceuticos ROVI?

For the upcoming 12 months, dividends amounting to 1.69 EUR are expected. This corresponds to a dividend yield of 2.29 %.

In which sector is Laboratorios Farmaceuticos ROVI located?

Laboratorios Farmaceuticos ROVI is assigned to the 'Health' sector.

Wann musste ich die Aktien von Laboratorios Farmaceuticos ROVI kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Laboratorios Farmaceuticos ROVI from 7/10/2024 amounting to 1.104 EUR, you needed to have the stock in your portfolio before the ex-date on 7/8/2024.

When did Laboratorios Farmaceuticos ROVI pay the last dividend?

The last dividend was paid out on 7/10/2024.

What was the dividend of Laboratorios Farmaceuticos ROVI in the year 2023?

In the year 2023, Laboratorios Farmaceuticos ROVI distributed 0.956 EUR as dividends.

In which currency does Laboratorios Farmaceuticos ROVI pay out the dividend?

The dividends of Laboratorios Farmaceuticos ROVI are distributed in EUR.

Scope 1 - Direct Emissions	6,693
Scope 2 - Indirect emissions from purchased energy	616
Scope 3 - Indirect emissions within the value chain	10,352
Total CO₂ emissions	7,309
CO₂ reduction strategy	✅
Coal energy	❌
Nuclear power	❌
Animal experiments	✅
Fur & Leather	—
Pesticides	—
Palm Oil	—
Tobacco	❌
Genetically modified organisms	❌
Climate concept	—
Sustainable forestry	—
Recycling regulations	✅
Environmentally friendly packaging	❌
Hazardous substances	✅
Fuel consumption and efficiency	✅
Water consumption and efficiency	✅

Percentage of female employees	53
Percentage of women in management	—
Percentage of Asian employees	—
Share of Asian management	—
Percentage of Hispanic/Latino employees	—
Hispano/Latino Management share	—
Percentage of Black employees	—
Black Management Share	—
Percentage of white employees	—
White Management Share	—
Adult content	❌
Alcohol	❌
Weapons	—
Firearms	❌
Gambling	❌
Military contracts	❌
Human rights concept	✅
Privacy concept	—
Occupational health and safety	✅
Catholic	✅

Environmental reporting	✅
Stakeholder Engagement	✅
Call Back Policies	✅
Antitrust law	❌

Stock Exchange	Laboratorios Farmaceuticos ROVI Ticker
BME	ROVI.MC
DÜSSELDORF	41L.DU
FRANKFURT	41L.F
LONDON	0ILL.L
LONDON STOCK EXCHANGE	0ILL.L
MADRID	ROVI.MC
MUNICH	41L.MU
PNK	LABFF
SIX	41L.SW

Laboratorios Farmaceuticos ROVI Ticker	Laboratorios Farmaceuticos ROVI FIGI
ROVI:SM	BBG000QP0656
ROVI:SQ	BBG000QP07P2
ROVIE:TQ	BBG000QTYHG5
41L:GR	BBG000RL1HQ6
41L:GF	BBG000RL1J37
41L:GD	BBG000RL1JP3
41L:GS	BBG000RL1KB5
41L:GM	BBG000RL1KN2
41L:GB	BBG000RL1KS7
ROVI:EO	BBG000S7S7K5
ROVI:XE	BBG000S7S8W0
ROVI:XL	BBG000S7S930
ROVI:E1	BBG000S7SD13
ROVI:XT	BBG000S7SD86
ROVI:XW	BBG000S7SDJ4
ROVI:EU	BBG000S7SF45
ROVIE:S1	BBG003YRZY67
ROVIE:EB	BBG004LMQ7N0
ROVIE:IX	BBG004M0GNR9
ROVI:XV	BBG00591R8J9
ROVIE:B3	BBG006T6LWV3
ROVIE:L3	BBG006T9XNL5
ROVIE:PO	BBG008H0D7V9
ROVIE:BQ	BBG009L20CZ7
ROVIUSD:EO	BBG00BYDY092
ROVIUSD:XH	BBG00BYDY0D7
ROVIUSD:XF	BBG00BYDY0G4
ROVIUSD:XE	BBG00BYDY0J1
ROVIUSD:XJ	BBG00BYDY0K9
ROVIUSD:XL	BBG00BYDY0L8
ROVIUSD:XG	BBG00BYDY0M7
ROVIUSD:XO	BBG00BYDY0N6
ROVIUSD:XS	BBG00BYDY0S1
ROVIUSD:XA	BBG00BYDY0T0
ROVIUSD:E1	BBG00BYDY0V7
ROVIUSD:XT	BBG00BYDY0W6
ROVIUSD:XW	BBG00BYDY0X5
ROVIUSD:XU	BBG00BYDY0Y4
ROVIUSD:XV	BBG00BYDY0Z3
ROVIUSD:EU	BBG00BYDY190
41L:QT	BBG00DB57214
ROVI:XM	BBG00J9VW763
0ILL:LN	BBG00JHVW8P1
ROVI:XX	BBG00JN7NXK7
ROVIUSD:XX	BBG00JN8GMY2
41L:SW	BBG00LVDP5T0
41L:BW	BBG00LVDP609
ROVIE:T1	BBG00NLK4HY2
ROVIE:I2	BBG00NQCS7B6
ROVI:X2	BBG00Q6RC3Z8
41L:TH	BBG00QJ7DNZ3
ROVIN:MM	BBG00RPL6PP7
ROVIN:MU	BBG00RPL6PR5
ROVIE:L1	BBG00Y92RXZ1
LABFF:US	BBG00YD8S1B8
LABFF:PQ	BBG00YD8S1R1
LABFF:UV	BBG00YD8S1S0
ROVIE:S4	BBG00YJ80ZQ1
ROVIGBP:XS	BBG00ZLHDFK1
ROVIGBP:XH	BBG00ZLHDFN8
ROVIGBP:XF	BBG00ZLHDFR4
ROVIGBP:XE	BBG00ZLHDFV9
ROVIGBP:XL	BBG00ZLHDFX7
ROVIGBP:XG	BBG00ZLHDFY6
ROVIGBP:XO	BBG00ZLHDFZ5
ROVIGBP:XA	BBG00ZLHDG38
ROVIGBP:XT	BBG00ZLHDG56
ROVIGBP:XW	BBG00ZLHDG65
ROVIGBP:XU	BBG00ZLHDG74
ROVIGBP:XV	BBG00ZLHDGB9
ROVIGBP:XM	BBG00ZLHDGC8
ROVIGBP:EU	BBG00ZLHDGL8
41L:GZ	BBG012DS4VG8
ROVIE:QX	BBG0146TT3C9
ROVIE:QE	BBG0146TTCL9
41L:LA	BBG018H8PJV2
41L:LU	BBG018J2BL25

2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024e	2025e	2026e	2027e	2028e
0.06	0.08	0.11	0.1	0.13	0.14	0.16	0.18	0.2	0.22	0.24	0.25	0.27	0.28	0.3	0.38	0.42	0.65	0.82	0.83	0.82	0.91	1.09	1.25	1.3
-	30.16	28.05	-4.76	27.00	11.02	12.06	16.46	9.24	7.96	9.68	3.36	7.72	3.77	10.18	25.74	9.97	54.65	26.08	1.47	-1.09	10.73	20.04	15.05	3.51
68.25	71.95	71.43	68.00	72.44	67.38	60.13	62.50	62.69	60.83	60.08	60.16	57.74	60.73	57.43	56.17	57.52	59.26	63.53	59.35	-	-	-	-	-
43	59	75	68	92	95	95	115	126	132	143	148	153	167	174	214	241	384	519	492	0	0	0	0	0
3	3	13	18	28	25	26	19	21	25	27	21	28	19	17	43	78	183	255	220	223	273	370	458	463
4.76	3.66	12.38	18.00	22.05	17.73	16.46	10.33	10.45	11.52	11.34	8.54	10.57	6.91	5.61	11.29	18.62	28.24	31.21	26.54	27.20	30.07	33.94	36.52	35.67
14	4	10	15	23	20	24	18	19	23	24	19	26	17	17	39	61	153	199	170	169	205	276	352	410
-	-71.43	150.00	50.00	53.33	-13.04	20.00	-25.00	5.56	21.05	4.35	-20.83	36.84	-34.62	-	129.41	56.41	150.82	30.07	-14.57	-0.59	21.30	34.63	27.54	16.48
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
50	50	50	50	49.9	49.6	49.7	49.7	49.7	49.8	49.89	49.54	49.03	49.26	51.22	55.18	55.39	55.4	53.47	53.19	0	0	0	0	0
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Own the gold standard ✨ in financial data & analytics fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Price

Price

TickerROVI.MC

ISINES0157261019

WKNA0M0GQ

Laboratorios Farmaceuticos ROVI stock price

Price

Overview

Intraday Feature

Total Return and Relative Price Change

Interpretation and Investment

Laboratorios Farmaceuticos ROVI Stock Price History

Laboratorios Farmaceuticos ROVI Revenue, EBIT, Net Income ES0157261019 · A0M0GQ

Revenue, EBIT and Profit

Understanding Revenue, EBIT, and Income

Yearly Analysis and Comparisons

Utilizing Expectations for Investment

Investment Insights

Laboratorios Farmaceuticos ROVI Revenue, EBIT and net profit per share

Laboratorios Farmaceuticos ROVI Income Statement, Balance Sheet, Cash Flow Statement

Keystats

Revenue and Growth

Gross Margin

EBIT and EBIT Margin

Income and Growth

Shares Outstanding

Interpreting Year to Year Comparison

Expectations and Predictions

Balance Sheet

Understanding the Balance Sheet

Assets

Liabilities

Equity

Year-to-Year Analysis

Interpreting the Data

Laboratorios Farmaceuticos ROVI stock margins ES0157261019 · A0M0GQ

Margin

Understanding Gross Margin

EBIT Margin Analysis

Revenue Margin Insights

Interpreting Expectations

Comparative Analysis

Laboratorios Farmaceuticos ROVI Margin History

Laboratorios Farmaceuticos ROVI Stock Sales Revenue, EBIT, Earnings per Share ES0157261019 · A0M0GQ

Revenue, EBIT and Earnings per share

Revenue Per Share

EBIT Per Share

Income Per Share

Expected Values

Laboratorios Farmaceuticos ROVI Revenue, EBIT and net profit per share

Laboratorios Farmaceuticos ROVI business model

Laboratorios Farmaceuticos ROVI SWOT Analysis

Strengths

Weaknesses

Opportunities

Threats

Laboratorios Farmaceuticos ROVI Eulerpool Fair Value

Fair Value

Understanding Fair Value

Income-Based Fair Value

Revenue-Based Fair Value

Dividend-Based Fair Value

Expectations and Forecasts

Comparative Analysis

Laboratorios Farmaceuticos ROVI historical P/E ratio, EBIT, and P/S ratio.

Laboratorios Farmaceuticos ROVI shares outstanding ES0157261019 · A0M0GQ

Revenue, EBIT and Earnings per share

Revenue Per Share

EBIT Per Share

Income Per Share

Expected Values

Laboratorios Farmaceuticos ROVI dividend history and estimates ES0157261019 · A0M0GQ

Dividend

Dividend Overview

Interpretation and Use

Investment Strategy

Laboratorios Farmaceuticos ROVI Dividend History

Laboratorios Farmaceuticos ROVI dividend payout ratio ES0157261019 · A0M0GQ

Payout ratio

Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Ticker
ROVI.MC

ISIN
ES0157261019

WKN
A0M0GQ